Portfolio
Click here to view all of Teuza's portfolio companies (print version - pdf format)
DTL
Teuza's holdings: 26%
www.pregenesys.com
A private company in which Teuza holds 26%.
DTL develops novel devices for monitoring pregnancy- at-risk based on emerging genomic
and proteomic research. Combined with home monitoring, DTL's diagnostics can be readily
packaged into a treatment plan for pregnant women who are at risk for pregnancy complications.
DTL discovered the gene for placenta protein 13 (PP13). Using a simple blood test,
DTL developed specific antibodies to detect PP13 in pregnant mother serum, as a new test
to diagnose mothers at risk for preeclampsia (PE), intrauterine growth retardation (IUGR)
and pre-term delivery (PTD). In cloning the PP13 gene, DTL found it to be a placental
specific phospholipase A produced during pregnancy in the placental outer layer and
released into the maternal blood stream. The amount of PP13 increases during the normal
course of pregnancy as the placenta enlarges. Blood tests of patients with PE and IUGR
correlates with a lower than normal level of PP13, whereas higher than normal concentration
accompanies PTD
DTL has a CE-Mark regulations approval to market its product in Europe accompanied by
specific marketing permits in Germany, the UK, France, Italy, Portugal and the Netherlands.
DTL is working to achieve the FDA approval and finished successfully several clinical studies.
DTL has signed a distribution and co-development agreement with WALLAC Oy (“Wallac”)
of Finland, a wholly owned subsidiary of PerkinElmer Inc, USA.
According to this agreement, Wallac will distribute worldwide (except Israel and Portugal)
the lead product of DTL – an ELISA diagnostic kit to predict the risk of developing
preeclampsia. In addition, Wallac and DTL will develop the next generation of this product
to fit robotic platforms of Wallac. DTL has granted to Wallac exclusive license to use its
patents to accomplish the co-development and to guide users in the utilization of the
diagnostic kits.
In consideration of this agreement, Wallac advanced DTL with a one-time payment of $3M
and in addition will pay DTL percentage of sales in proportion to the volume of sales.
In addition, the agreement defines the terms and conditions of the transfer prices of the
kits for the robotic platforms.
Wallac is the leading arm of PerkinElmer in genetic and prenatal diagnostics.
PerkinElmer is one of the world’s biotechnology leaders traded in the New York stock
exchange (“PKI”) at a $3 Billion market value and its annual turnover is $1.7 Billion.
Recently DTL raised $2.4M in a private placement according to a pre-money valuation of $12.4M.
P.O.B 25266 Haifa 31250 Israel Tel: 972 4 8728788 Fax: 972 4 8729393 E-mail: teuza@teuzafund.com